Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
HEALIUS LIMITED (HLS)ASX AI Signals has generated 3 signal for HLS during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest HLS Signals | |
| 02/06/2026 | BUY |
| 14/05/2026 | SELL |
| 06/05/2026 | SELL |
HLS Share Price | |
| Current Price | $0.375 |
| 52 Week High | $1.040 |
| 52 Week Low: | $0.315 |
| Trading at (% of 52 Week High) | 36.06% |
Healius Limited (ASX: HLS) is an Australian healthcare company that operates diagnostic imaging, pathology, and day hospital services. It provides medical testing, imaging, and treatment solutions to patients and healthcare professionals across Australia.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The BUY signal for HEALIUS LIMITED (HLS) at the current price of 0.3350 is supported by positive momentum indicators and potential sector growth. However, moderate market volatility and company-specific risks temper the confidence level.
Investing.com -- Australian Prime Minister Anthony Albanese announced on Sunday that the upcoming federal budget will include a significant funding boost for Medicare urgent care clinics, according to a report from Bloomberg.
The government plans to allocate an additional A$1.8 billion ($1.3 billio Australian Clinical Labs withdrew its takeover offer for Healius, citing the deteriorating performance of its pathology services rival rather than opposition from Australia’s competition regulator.
Continue reading The Australian healthcare company’s base pathology business delivered revenue growth of 4% in 2H and management believes it has addressed the division’s cost base. “Volume growth will be a key focus for FY 2024 to drive margin,” analyst David Stanton says in a note. “In terms of pathology Ebit margi Communications enhancements to improve the doctor and patient experience
SYDNEY, Australia & BELMONT, Calif., November 02, 2022--(BUSINESS WIRE)--Healius Limited (Healius) (ASX: HLS), one of Australia’s leading healthcare companies, has selected RingCentral, Inc. (NYSE: RNG) to deploy an integrated ST. LOUIS, August 30, 2022--(BUSINESS WIRE)--C2N Diagnostics, a leader in advanced brain health diagnostics, and Healius Ltd (ASX:HLS), one of Australia's leading listed healthcare companies, today announced a partnership that will aim to bring C2N’s PrecivityAD™ blood test and related brain health Latest HEALIUS LIMITED(HLS) News
Australia pledges A$1.8 billion for Medicare clinics amid widening deficit fears
Australian Clinical Labs Withdraws Takeover Offer for Healius
Health Care Roundup: Market Talk
RingCentral Selected by Healius to Transform Telephony and Contact Center Platform Australia-wide
C2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial